Tim Yap
Vice President and Head of Clinical Development, Therapeutics Discovery Division The University of Texas MD Anderson Cancer Center
Seminars
Thursday 29th January 2026
Exploring WRN Inhibition in MSI Tumors to Expand Synthetic Lethality Strategies Beyond PARP
2:30 pm
• See how the MD Anderson Cancer Center is advancing first-in-human trial data for WRN inhibitors in MSI solid tumors
• Interpreting translational relevance and biomarker integration
• Positioning WRN as a synthetic lethality target beyond PARP
